Fairvalue-Calculator Fairvalue-Calculator
EN DE

ApicHope Pharmaceutical Group (300723) Fair Value & Analysis

Healthcare · CN · Market cap 15.0B CNY

Price¥33.12
Fair Value¥13.64
Upside-58.8%
Quality94/100
Evidence: Low Range ¥10.23 – ¥17.05

Fair value as of: Jun 24, 2026

Analysis

ApicHope Pharmaceutical Group (300723) currently trades at ¥33.12, while our model-based Fair Value estimate is ¥13.64 — implying the stock looks roughly 58.8% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxiangqingjie oral liquids, epinastine hydrochloride granules, clindamycin palmitate hydrochloride granules, clindamyxin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drops, montelukast sodium oral granules, oseltamivir phosphate capsules, and levocetirizine dihydrochloride oral drops. It also provides chronic disease drugs, including aciclovir for injection, hepatocyte growth-promoting factor for injection, pentoxifylline injection, kangshen and niaoqingshu granules, shenbo lotion, compound monoammonium glycyrrhizinate s and lansoprazole for injection, ome…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is ApicHope Pharmaceutical Group (300723) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥13.64 versus a price of ¥33.12 — about −59% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 300723?
Our 21-model fair value for ApicHope Pharmaceutical Group is ¥13.64 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥33.12.
What is the quality score of 300723?
ApicHope Pharmaceutical Group has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.